Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
12 participants
OBSERVATIONAL
2024-06-10
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Evaluate the SpO2 accuracy of the oximeter component of the ProSomnus RPMO2 Device during non-motion conditions over the range of 70-100% SaO2 by comparison to SaO2 values determined by arterial blood sample specimen analyzed by a CO-oximeter.
2. Evaluate the pulse rate performance simultaneously collected over the SpO2 range.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-resolution Oximetry to Diagnose Obstructive Sleep Apnea
NCT04366193
Outcome and Treatment of Complex Sleep Apnea
NCT01137214
Oxygen Saturation Patterns in Post-Op Patients at Risk for Obstructive Sleep Apnea
NCT01078207
Accuracy of Pulse Oximeters With Profound Hypoxia
NCT03710980
Evaluating an Under-mattress Sleep Monitor Compared to a Peripheral Arterial Tonometry Device in the Diagnosis of Obstructive Sleep Apnea
NCT04778748
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Arterial blood draws within the hypoxic plateaus will be performed, with draws occurring no less than 30 seconds after reaching a plateau and no less than 20 seconds apart. Five blood draws will be taken at each plateau. Plateaus will be determined using the reference transmittance pulse oximeter and are defined as a change in SpO2 on the reference pulse oximeter of no more than 1% over a duration of 20 seconds. Sampling will not continue if the blood oxygen saturation destabilizes between blood draws.
Time in low O2 saturation decades (i.e., 70-80% and 80-90%) will be limited to the minimum amount of time required to obtain test data and will not exceed 10 minutes. The saturation level at each plateau and the number of plateaus may vary among participants. Arterial pressure, ECG, heart rate, EtCO2, respiratory rate, and FiO2 will be monitored during testing. Extra samples may be collected at the discretion of the PI. The controlled desaturation protocol is expected to take approximately 30 to 60 minutes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers
Health adult volunteers will undergo a controlled desaturation to collect data for validation of the RPMO2 device.
ProSomnus RPMO2
The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ProSomnus RPMO2
The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In good health with no evidence of medical problems.
* Ability to provide informed consent and willingness to comply with the study procedures.
* Ability to undergo controlled hypoxemia to the levels outlined in the desaturation profile.
* Adequate dentition for an oral appliance.
* Ability to breathe through the nose comfortably.
Exclusion Criteria
* Known history of heart, lung, kidney, or liver disease.
* Diagnosis of asthma or sleep apnea.
* Diagnosis of diabetes.
* Presence of a clotting disorder.
* Presence of hemoglobinopathy or history of anemia that, in the opinion of the PI, makes the individual unsuitable for participation.
* Current smoker.
* History of fainting or vasovagal response.
* History of sensitivity to local anesthesia.
* Unacceptable collateral circulation based on exam (Allen's test).
* Pregnancy or lactation.
* Resting heart rate \> 120 bpm.
* Systolic BP \> 150, diastolic BP \> 90.
* Carboxyhemoglobin level \> 3%.
* Presence of any other condition that, in the opinion of the PI, makes the individual unsuitable for participation.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ProSomnus Sleep Technologies
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB23-1003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.